IPO registrations (S-1, F-1) · Registrants
Telix Pharmaceuticals Ltd
- SEC CIK
- 2007191 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2024-05-17, last 2024-06-05; 1 initial registration, 1 amendment
- Outcome
- Declared effective 2024-11-12; withdrawal requested 2024-06-14
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- C3
- Business address
- 55 FLEMINGTON ROAD, North Melbourne, C3 3051
- Ticker
- TLX, TLPPF (Nasdaq, OTC)
- EDGAR entity type
- other
- Insiders and CEO pay
- Telix Pharmaceuticals Ltd on the corporate pages
Offering terms
- Shares offered
- 17,000,000
- Listing
- Nasdaq under the symbol TLX
- Lead underwriters
- Jefferies; Morgan Stanley; Truist Securities; William Blair
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Telix Pharmaceuticals Ltd EXACT (CIK (EXACT))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-05-17 | F-1 | F-1 (foreign registration) | Telix Pharmaceuticals Ltd | 0001140361-24-026584 ↗ |
| 2024-06-05 | F-1/A | F-1/A (amendment) | Telix Pharmaceuticals Ltd | 0001140361-24-028932 ↗ |
| 2024-06-14 | RW | RW (withdrawal request) | Telix Pharmaceuticals Ltd | 0001140361-24-030120 ↗ |
| 2024-06-14 | RW | RW (withdrawal request) | Telix Pharmaceuticals Ltd | 0001140361-24-030136 ↗ |
| 2024-11-12 | EFFECT | EFFECT (declared effective) | Telix Pharmaceuticals Ltd | 9999999995-24-003460 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | F-1/A | registration statement | $11.87 | 17,000,000 | $201,790,000 | Nasdaq TLX | 4 | primary document; price line, shares headline, proceeds computed, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Behrenbruch Christian | Director,Officer | MD & Group CEO | 2 | 2026 | |
| McDonald Marie Elizabeth | Director | 1 | 2026 | ||
| Skinner Jann Elizabeth | Director | 1 | 2026 | ||
| Cade David Norman | Officer | Group Chief Medical Officer | 1 | 2026 | |
| Nelson Mark Alexander | Director | 1 | 2026 | ||
| Patti Darren Joel | Officer | Group Chief Operating Officer | 1 | 2026 | |
| Smith Darren Charlton | Officer | Group Chief Financial Officer | 3 | 2026 | |
| GILL DAVID N | Director | 1 | 2026 | ||
| Jellison William R | Director | 1 | 2026 | ||
| Rivas Maria | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Telix Pharmaceuticals Ltd | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, C3 first:
- Pharmaxis Ltd. C3
- Propanc Biopharma, Inc. C3
- Benitec Biopharma LTD/ADR C3
- Parnell Pharmaceuticals Holdings Ltd C3
- Immuron Ltd C3
- Beroni Group Ltd C3
- Medlab Clinical Ltd. C3
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
In other datasets, the same topic (Health) in C3:
- Form D issuer: Botanix Pharmaceuticals Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health